prescriptions are not valid in Canada
TLR4 enhances TGF- signaling and hepatic fibrosis
Talk to your primary care provider about screening for this condition
Potential Side Effects Common side effects of GLP-1 agonists, particularly during the initial weeks of weight loss treatment, include: Nausea Vomiting Diarrhea Headache Constipation Decreased appetite Pain in the right or middle upper stomach area Fatigue Dizziness Indigestion Injection site reactions (e.g., injection site rash, erythema) Conclusion GLP-1 agonists represent a promising pharmacological approach to weight management, offering significant benefits for individuals struggling with obesity or being overweight
A 2024 study looked at postmenopausal women on semaglutide who were overweight or obese (the median BMI was 36)
Retatrutide An investigational triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors, demonstrating body-weight change of up to 24.2% in phase 2 trials alongside improvements in cardiometabolic parameters and hepatic steatosis
